Mayo Clinic researchers identify drug resistance factors for advanced prostate cancer
ROCHESTER, Minn. — In a new study published in Molecular Cancer Research, Mayo Clinic researchers identified critical genomic changes in response to abiraterone acetate/prednisone, a standard treatment option for men with progressive, incurable and castration-resistant prostate cancer. Liewei Wang, M.D., Ph.D. "We defined a potential strategy for both responders and nonresponders of the drug that may help men overcome resistance and prolong survival," says Liewei Wang, M.D., Ph.D., the Bernard and Edith Waterman Director, Pharmacogenomics…
Source: Mayo Clinic Research News - Category: Research Source Type: news
More News: Abiraterone Acetate | Cancer | Cancer & Oncology | Prednisone | Prostate Cancer | Research | Study